New study checks if dupixent makes life better for severe asthma patients

NCT ID NCT06018441

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 112 adults with severe asthma who were starting treatment with dupilumab (Dupixent). Researchers measured changes in quality of life using a standard questionnaire at 12, 24, and 52 weeks. The goal was to see if the drug helps people feel better and breathe easier in everyday life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

dupilumab (Dupixent)

What this could lead to

If successful, this could show that dupilumab improves daily life for people with severe asthma, supporting its use in routine care.

What could go wrong

This is an observational study, not a controlled trial, so results may be less reliable. It also only includes people already starting dupilumab, which may bias outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Investigational Site

    France, France